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Abstract
Background: Prolonged periods of high glucose exposure results in human islet dysfunction in vitro. The underlying
mechanisms behind this effect of high glucose are, however, unknown. The polypyrimidine tract binding protein (PTB) is
required for stabilization of insulin mRNA and the PTB mRNA 39-UTR contains binding sites for the microRNA molecules miR-
133a, miR-124a and miR-146. The aim of this study was therefore to investigate whether high glucose increased the levels of
these three miRNAs in association with lower PTB levels and lower insulin biosynthesis rates.
Methodology/Principal Findings: Human islets were cultured for 24 hours in the presence of low (5.6 mM) or high glucose
(20 mM). Islets were also exposed to sodium palmitate or the proinflammatory cytokines IL-1b and IFN-c, since saturated
free fatty acids and cytokines also cause islet dysfunction. RNA was then isolated for real-time RT-PCR analysis of miR-133a,
miR-124a, miR-146, insulin mRNA and PTB mRNA contents. Insulin biosynthesis rates were determined by radioactive
labeling and immunoprecipitation. Synthetic miR-133a precursor and inhibitor were delivered to dispersed islet cells by
lipofection, and PTB was analyzed by immunoblotting following culture at low or high glucose. Culture in high glucose
resulted in increased islet contents of miR-133a and reduced contents of miR-146. Cytokines increased the contents of miR-
146. The insulin and PTB mRNA contents were unaffected by high glucose. However, both PTB protein levels and insulin
biosynthesis rates were decreased in response to high glucose. The miR-133a inhibitor prevented the high glucose-induced
decrease in PTB and insulin biosynthesis, and the miR-133a precursor decreased PTB levels and insulin biosynthesis similarly
to high glucose.
Conclusion: Prolonged high-glucose exposure down-regulates PTB levels and insulin biosynthesis rates in human islets by
increasing miR-133a levels. We propose that this mechanism contributes to hyperglycemia-induced beta-cell dysfunction.
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Introduction
Type 2 diabetes is characterized by a decrease in b-cell mass
and function either alone or in combination with insulin
resistance, which results in an insufficient insulin production and
subsequent hyperglycemia [1–3]. Glucose is the main stimulator of
b-cell function, regulating various cellular processes including
insulin gene expression [4,5], insulin biosynthesis [6–8] and insulin
secretion [9]. Nevertheless, it has long been known that prolonged
exposure to high glucose concentrations results in human islet
dysfunction and death [10], a phenomenon known as glucotoxicity
[11]. More specifically, culture of human islets for 4 to 9 days
resulted in lowered insulin mRNA contents, insulin biosynthesis
rates, insulin/proinsulin ratios, glucose-stimulated insulin release
and insulin contents [10,12]. Beta-cell function can also be
impaired in response to certain free fatty acids, such as palmitic
acid [13,14], in a process called lipotoxicity [15]. In addition, not
only metabolic factors, but also proinflammatory cytokines
promote islet dysfunction leading to loss of glucose-stimulated
insulin secretion, lowered insulin contents [16,17], and ultimately,
b-cell death through apoptosis [18,19]. Loss of b-cell mass as a
cause of diabetes was long the hallmark of type 1 diabetes, but has
in recent years been widely recognized as an important factor in
progressive beta-cell dysfunction in type 2 diabetes as well [1,2,20].
The relative or absolute insulin deficiency observed in diabetes
is in many cases due to a defective insulin biosynthesis insufficient
to meet the demand for extended periods of insulin hypersecretion
[21,22]. Several factors are required for controlling the insulin
biosynthesis including, but not limited to, transcription of the
insulin gene, insulin mRNA stability, translation of the insulin
mRNA, and the ability of the endoplasmic reticulum to balance
the vast production of proinsulin with the unfolded protein
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translation is dependent on both the rate of insulin gene
transcription and the stability of the transcript [7,26], but due to
the high copy number of insulin mRNA in the b-cells (app. 50 000
copies/cell at basal conditions), the level of insulin mRNA is
controlled mainly by changes in mRNA stability [6,21].
The regulation of mRNA stability is determined by interactions
between regulatory cis-elements in the mRNA molecule and
RNA-binding proteins. These interactions are in turn sensitive to
many different developmental and environmental stimuli such as
cytokines, hormones and nutrients, but also environmental stress
such as hypoxia and hyperglycemia [27]. A dominating mediator
Figure 1. Effects of high glucose, palmitate or cytokines on human islet miR-133a, miR-124a and miR-146 levels. Human islets in
groups of 100 were cultured for 24 hours in CMRL 1066 medium with 5.6 mM glucose (control), 20 mM glucose, 5.6 mM glucose and 0.5 mM sodium
palmitate solubilized in 0.5% BSA, 20 mM glucose and 0.5 mM sodium palmitate + 0.5% BSA, or 5.6 mM glucose and 50 U/ml IL-1b + 1000 U/ml IFN-
c. The islets were then harvested for RNA isolation, cDNA synthesis and real-time PCR analysis. Primers specific for miR-133a (A), miR-124a (B) and
miR-146 (C) were used. Results are expressed per let7c and normalized to control. Results are means 6 SEM for 5 independent (islets from 5 different
donors) experiments. * denotes p,0.01 using paired Student’s t-test when comparing vs. control.
doi:10.1371/journal.pone.0010843.g001
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binding protein (PTB). This protein has been shown to induce
stability by binding to a conserved sequence in the 39- untranslated
region (UTR) of insulin mRNA [6]. Interestingly it has also been
shown that PTB stabilizes mRNA encoding for insulin granule
proteins [28], suggesting that PTB stabilizes mRNAs of proteins
involved in the entire secretory pathway [29].
MicroRNAs as regulators of protein expression is an evolving
research field. By binding to mRNAs, miRNAs can induce
translational repression leading to lowered protein levels. It has
recently been suggested that certain miRNAs contribute to the
pathogenesis of diabetes and may control pancreatic b-cell
function [30]. Two of these miRNAs, miR-124a and miR-133a,
have recently been shown to target PTB in neuronal and muscle
cells, respectively [31,32]. In addition, using the TargetScan 3.1
software a putative binding site for miR-146 in rat PTB mRNA
can be predicted. Interestingly, this miRNA is highly upregulated
by cytokines in b-cells [33]. Taken together, at least three different
miRNAs may control insulin mRNA translation by regulating
PTB levels. The aim of this study was therefore to investigate
whether three pathogenetic factors in type 2 diabetes all known to
impair beta-cell function in vitro, namely high glucose, sodium
palmitate and proinflammatory cytokines, increase miR-124a,
miR-133a or miR-146 levels in association with lower PTB levels
and lower rates of insulin biosynthesis. We report here that miR-
133a is induced by high glucose in human islet cells leading to
lower PTB levels.
Methods
Islet isolation, culture, and exposure to different beta-cell
inhibitory substances
Human pancreatic islets were kindly provided by Prof. Olle
Korsgren (Dept. of Radiology, Oncology and Clinical Immunol-
ogy, Uppsala University Hospital, Uppsala, Sweden), through the
Uppsala facility for the isolation of human islets from Scandina-
vian brain-dead individuals. The human pancreatic islets were
isolated from the pancreas of brain-dead organ donors using
collagenase digestion and Biocoll gradient centrifugation [34].
After isolation, the islets were cultured free-floating in Sterilin
dishes in CMRL 1066 medium containing 5.6 mM glucose, 10%
fetal calf serum (FCS), and 2 mM L-glutamine for 1–5 days.
The islet beta-cell percentages determined using Newport
Green staining followed by fluorescence microscopy were
routinely 30–60%.
To evaluate islet functional quality, batches of twenty islets were
perfused with Krebs-Ringer bicarbonate HEPES buffer (KRBH)
containing 2 mg/ml human albumin and 1.67 mmol/l glucose at
a flow rate of 0.3 ml/min. The glucose concentration was
increased to 16.7 mM after a 30-min period. Fractions for insulin
Figure 2. High glucose, palmitate or cytokines do not affect human islet PTB1 mRNA and PTB2 mRNA levels. Human islets were
cultured and analyzed by real-time RT-PCR as given in Figure 1. Primers specific for PTB1 (A) and PTB2 (B) were used. Results are means 6 SEM for 5
independent experiments.
doi:10.1371/journal.pone.0010843.g002
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human islets used in different experiments of this study the mean
stimulation index in response to glucose was 7.862.4.
Following the initial culture period, islets were cultured for an
additional 24 hours in CMRL 1066 containing 10% FCS +2m M
glutamine and one of the following supplements: 20 mM glucose;
5.6 mM glucose +0.5 mM sodium palmitate solubilized in 0.5%
(weight/volume) fatty acid and lipopolysaccaride free bovine
serum albumin (BSA) (Sigma); 20 mM glucose +0.5 mM sodium
palmitate solubilized in 0.5% BSA; or 5.6 mM glucose + recombi-
nant human interleukin-1b (IL-1b) (50 units/ml) (PeproTech,
London, U.K.) and c-interferon (IFN-c) (1,000 units/ml)
(PeproTech).
Real-time RT-PCR analysis
Total islet RNA was purified in Uppsala using the Ultraspec
RNA reagent (Biotecx, Houston, TX) according to the instructions
of the manufacturer, with the exception that isopropanol-induced
RNA precipitation was prolonged at 220 C to ensure efficient
miRNA precipitation. All human islet RNA material was sent
coded to the Hagedorn Research Institute in Denmark, where the
real-time qPCR analyses were performed in a blinded fashion.
miRNA. The extracted RNA from human donors was
converted to cDNA with the TaqMan microRNA Reverse
Transcription kit by the individual RT reaction protocols
provided by the manufacturer (Applied Biosystems). For
detection of the mature microRNAs, the TaqMan microRNA
Figure 3. Effects of high glucose, palmitate or cytokines on human islet PTB protein levels. Human islets were cultured as given in
Figure 1. Islets were washed and harvested for SDS-PAGE and immunoblotting with anti-PTB antibodies. PTB bands were quantified and normalized
to total protein loading using Amidoblack staining. Lower panel shows PTB immunoreactivity and Amidoblack staining of total protein loading from
one representative experiment. Results are means 6 SEM for 4 independent experiments. * denotes p,0.05 using paired Student’s t-test when
comparing vs. control.
doi:10.1371/journal.pone.0010843.g003
Figure 4. High glucose, palmitate or cytokines do not affect human islet insulin mRNA levels. Human islets were cultured and analyzed
by real-time RT-PCR as given in Figure 1. Primers specific for insulin mRNA were used. Results are means 6 SEM for 5 independent experiments.
doi:10.1371/journal.pone.0010843.g004
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manufacturer. The microRNA results were normalized to
internal control microRNA (let7c).
mRNA. TaqMan Reverse Transcription Reagents and
TaqMan Gene Expression Assays were used for production of
cDNA and detection by qRT-PCR, respectively, according to
manufacturer (Applied Biosystems). The genes of interest were
normalized to an internal control (PPIA). Sequences of primers
used for semi-quantification of miRNA and mRNA can be
provided upon request.
For both types of gene expression the target genes were
quantified by relative quantification using the comparative CT
method.
miRNA transfection
Human islets, in groups of 200, were dispersed in 0.5% trypsin
for 5 min at 37uC and then treated with DNase I (Amersham Life
Science, Piscataway, NJ, USA) (30 units/ml) for 2 min. The
resulting islet cell suspensions were placed in non-attachment
plates and transfected with the pre-designed miR-133a precursor
(Ambion; AM17100), a small, double-stranded and chemically
modified RNA molecule designed to mimic the effects of miR-
133a, the pre-designed miR-133a inhibitor (Ambion; AM17000), a
single stranded and chemically modified RNA-molecule designed
to nullify miR-133a activity, or with the negative control miR
oligonucleotide (Ambion). To introduce these siRNAs into the cells
a liposome reagent, Dharmafect I (Dharmacon), was used.
Transfection was carried out according to manufacturers’
recommendations using 2 ml Dharmafect and 100 nM of the
miRNA oligonucleotides. The transfection was performed in
500 ml serum- and antibiotics-free medium for 2 hours after which
the cells were cultured for two days in complete CMRL 1066
medium. The cells were then cultured for another 24 hours at 5.6
or 20 mM glucose before harvest and immunoblot analysis.
PTB immunoblot analysis
Islet cells were washed once with PBS and then lysed with SDS
sample buffer; 2% SDS, 5% b-mercaptoethanol, 100 mM Tris-
HCL pH 6.8, 10% glycerol and bromophenolblue. The protein
samples were boiled for 5 min before separation on a 9% SDS-
PAGE. The separated proteins were electrophoretically trans-
ferred to Hybond
TM-P membranes (Amersham Bioscience), which
were then pre-blocked in 2.5% BSA. The membranes were
hybridized with monoclonal mouse anti-PTB antibody (Zymed)
and monoclonal mouse anti-tubulin antibody (Santa Cruz) for one
hour. The horseradish peroxidase conjugated anti-mouse or anti-
rabbit antibodies were used as secondary antibodies and
luminescence detected with the ECL system (Amersham Biosci-
ence). The resulting bands were then digitalized using the Kodak
4000MM system and the optical densities were measured using the
Kodak Molecular Imaging Software.
Insulin and total protein biosynthesis
Twenty islets in duplicate groups were incubated for 2 h in
100 ml KRBH buffer supplemented with 0.2% bovine serum
albumin, 20 mM glucose and 50 mCi/ml L-[3,4,5-
3H] leucine
(GE Healthcare Life Sciences, Chalfont St. Giles, Buckingham-
shire, UK). The islets were then washed in Hank’s Balanced Salt
Solution and homogenized by sonication for 10 seconds in 200 ml
of a 50 mM glycine buffer (pH 8.8) supplemented with 0.25%
BSA. For insulin analysis, four 10 ml aliquots were mixed with
100 ml 50 mM glycine buffer supplemented with BSA and 0.1%
Triton X-100, and in duplicates supplemented with 10 mlo f
guinea pig anti-human insulin serum (Chemicon International,
Temecula, CA, USA) or 10 ml normal guinea pig serum (Harlan
Sera-Lab, Loughborough, Leicestershire, UK). One hundred ml
protein A-sepharose (GE Healthcare) were added, the tubes
tumbled at room temperature for 15 minutes and then washed
three times. For total protein biosynthesis, 10 ml aliquots were
precipitated with 10% trichloracetic acid. Samples were then
solubilized in Ultima Gold scintillation fluid and analyzed by
liquid scintillation counting.
Results
Effects of high glucose, sodium palmitate or cytokines on
miRNA expression in human islets
Exposure of islets to high glucose, sodium palmitate or cytokines
negatively affects beta-cell function and viability [10,16,17,35] by
distinct pathways [36] but in the case of high glucose and cytokines
also by partly overlapping pathways [2,35]. To clarify if the
inhibitory effects of these islet stressors were associated with
differential expression of specific miRNAs, we analyzed miR-133a,
miR-124a and miR-146 levels by semi-quantitative real-time RT-
PCR and normalized the results per let7c levels. Let7c is a miRNA
that has previously shown no variation in response to high glucose
[37] or cytokines (results not shown) in insulin producing cells.
Typical thresh-hold cycle numbers for miR-133a, miR-124a and
miR-146 were 28–30, 32–34 and 25–27, respectively, indicating a
relatively high abundance for miR-146, an intermediary abun-
dance for miR-133a and a low abundance for miR-124a. We
observed that a 24h exposure to 20 mM glucose resulted in a
doubling of miR-133a levels (Figure 1A). There was also a trend to
higher miR-133a levels in response to sodium palmitate
(Figure 1A), both at 5.6 and 20 mM glucose, but due to
considerable inter donor variation, this effect did not reach
statistical significance. A 24h exposure to cytokines did not affect
miR-133a levels (Figure 1A).
Table 1. Effects of glucose on human islet insulin biosynthesis.
5.6 mM Glucose 20 mM Glucose
Insulin Biosynthesis (DPM/islet) 624658 409649
Total Protein Biosynthesis (DPM/islet) 1230061560 959061220
Insulin Biosynthesis/Total Protein Biosynthesis (%) 5,360,5 4,360,4*
Islet in groups of 20 were cultured for 24 hours at 5.6 or 20 mM glucose and then labeled with
3H-leucine for two hours in a KRBH buffer containing BSA and 20 mM
glucose. Insulin was immunoprecipitated with guinea pig anti-insulin antibodies and protein A sepharose, and total proteins were precipitated with trichloroacetic acid.
Incorporated radioactivity was quantified by liquid scintillation counting and results are means 6 SEM for 4 observations.
*denotes p,0.05 using paired Student’s t-test when comparing vs. control.
doi:10.1371/journal.pone.0010843.t001
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levels. In this case, there was only a trend for higher levels of miR-
124a in response to high glucose and high glucose+sodium
palmitate (Figure 1B). The miR-124a levels were unaltered by
sodium palmitate and cytokines (Figure 1B).
Further, we observed a pronounced increase in the levels of
miR-146 in response to the cytokines IL-1b and IFN-c (Figure 1C)
in line with previous investigations demonstrating miR-146
induction by cytokines in b-cells [33]. Interestingly, miR-146
levels were significantly decreased in response to high glucose
(Figure 1C).
Effects of high glucose, sodium palmitate or cytokines on
PTB mRNA and PTB protein levels in human islets
Having observed that a deleterious concentration of glucose
and cytokines increased miR-133a and miR-146, respectively,
we next investigated whether PTB mRNA and PTB protein
levels were affected. The thresh-hold cycle numbers for PTB1
were 3–4 cycles lower (29 vs. 33 cycles) than those for PTB2,
indicating strong expression of PTB1 in human islet cells. None
of the experimental conditions altered PTB1- or PTB2 mRNA
levels (Figure 2A and 2B). However, PTB protein levels were
decreased by 30–40% in islets incubated in the presence of high
glucose or sodium palmitate (Figure 3) consistent with the
observation that miR-133a inhibits PTB mRNA translation by
binding to the 39-UTR of PTB mRNA [31,32], and in line with
the generally accepted notion that miRNAs often decrease
translation without affecting mRNAs t a b i l i t ya n dl e v e l s[ 3 8 , 3 9 ] .
No effect was observed in response to cytokines (Figure 3),
indicating that miR-146, which was strongly induced by
cytokines (Figure 1C), does not target PTB-mRNA in human
islet cells.
Effects of high glucose, sodium palmitate or cytokines on
insulin mRNA levels and insulin biosynthesis rates
PTB contributes to stabilization of insulin mRNA [6,28,40].
To determine whether a high glucose-induced decrease in PTB
protein levels affected insulin production, we analyzed insulin
mRNA levels and insulin biosynthesis rates. Although there
was a trend for lower insulin mRNA levels in islets exposed to
high glucose or sodium palmitate, no significant differences
were observed (Figure 4). In contrast, insulin biosynthesis rates,
when expressed as the percentage insulin biosynthesis of total
protein biosynthesis, were decreased by 20% in islets exposed
to high glucose for 24h (Table 1). Total protein synthesis rates
were not affected by high glucose (Table 1) indicating that a
lowered PTB level is associated with impaired insulin
production.
Effects of miR-133a precursor and miR-133a inhibitor on
islet PTB protein levels and insulin biosynthesis rates
To establish that the high glucose-induced increase in miR-
133a mediated the decrease in PTB protein levels, we introduced
the miR-133a precursor and the miR-133a inhibitor into
dispersed islet cells by lipofection. Two days later cells were
incubated for 24h at 5.6 or 20 mM glucose and PTB protein
levels were determined. Similarly to the experiments of Figure 3,
we observed a modest decrease in PTB protein levels in response
to the high glucose concentration (Figure 5A). This effect was
mimicked by the miR-133a precursor (Figure 5A). The miR-133a
inhibitor tended to increase PTB protein levels, both at low and
high glucose, but this effect did not reach statistical significance
(Figure 5A). In separate control experiments using fluorescein-
labeled siRNA as a marker for liposome-mediated uptake of
miRNA, transfection efficiency was assessed to approximately
50% (results not shown), which is in line with previous
assessments of liposome-mediated islet cell siRNA transfection
efficiency [41]. Using the same experimental setup, insulin
biosynthesis rates, but not total protein biosynthesis rates, were
decrease in human islet cells transfected with the miR-133a
precursor, both at low and high glucose concentrations (Table 2
and Figure 5B). The high glucose-induced decrease in insulin
biosynthesis was abolished by transfection with the miR-133a
inhibitor (Table 2 and Figure 5B).
Figure 5. Effects of high glucose, miR-133a precursor or miR-
133a inhibitor on human islet PTB protein levels (A) and insulin
biosynthesis rates (B). In A, human islet cells were dispersed by
trypsin treatment and lipofected with control RNA, miR-133a precursor
or miR-133a inhibitor using Dharmafect I. Two days after the lipofection
cells were cultured for another 24 hours in either 5.6 or 20 mM glucose.
Islets were washed and harvested for SDS-PAGE and immunoblotting
with anti-PTB antibodies. Lower panel shows PTB and tubulin
immunoreactivity from one representative experiment. In B, human
islets were transfected and cultured as in A and insulin biosynthesis
rates were determined as in Table 1. Insulin biosynthesis rates were
expressed as percentage insulin biosynthesis per total protein
biosynthesis. Results are means 6 SEM for 3–4 observations. * denotes
p,0.05 using paired Student’s t-test when comparing vs. control.
doi:10.1371/journal.pone.0010843.g005
miR-133a Is Induced by Glucose
PLoS ONE | www.plosone.org 6 May 2010 | Volume 5 | Issue 5 | e10843Discussion
Here we report that a high glucose concentration increased
miR-133a levels and decreased PTB protein levels, paralleled by
lowered insulin biosynthesis rates. Since the high glucose effects on
PTB protein levels and insulin biosynthesis rates were counter-
acted by the miR-133a inhibitor, and since the miR-133a
precursor mimicked the effects of high glucose, it is likely that
miR-133a binds to and inhibits the translation of PTB mRNA in
human islet cells, and that high-glucose decreases insulin
production, at least in part, by inducing miR-133a. Indeed,
miR-133a-induced inhibition of nPTB translation has previously
been demonstrated in neuronal cells [31], and it is known that
PTB mRNA contains similar miR-133a binding sites as those
characterized in nPTB [31]. PTB binds the pyrimidine rich tract
of the 39-UTR of insulin mRNA [6] and other mRNAs coding for
secretory proteins present in insulin granules of the beta-cell [28].
A mutation of the PTB-binding site [6,40] or siRNA-mediated
depletion of PTB protein levels [28] results in insulin mRNA
destabilization and lower insulin contents. Similarly, in this study a
lowered PTB protein level was associated with decreased insulin
biosynthesis. Somewhat surprisingly, insulin mRNA levels were
not significantly decreased in high glucose cultured islets. A
probable explanation for this finding is that high glucose promotes
increased insulin gene transcription in human islet cells [42,43].
Thus, the PTB depletion-induced insulin mRNA destabilization
may be counterbalanced by high glucose-induced de novo
formation of insulin mRNA. In line with this, it could be
speculated that insulin mRNA molecules that do not bind PTB are
transferred to a translationally inactive pool or compartment, as
observed in other cases [44]. Consequently, cellular PTB levels,
rather than total insulin mRNA levels, may determine actual
insulin translation rates.
MicroRNA-133a is abundantly expressed in muscle tissue, and
insulin-mediated down-regulation of miR-133a levels in human
skeletal muscle is attenuated in Type 2 diabetes [45]. In addition,
miR-133a contents are increased in cardiomyocytes taken from
human diabetic patients [46]. The pathophysiological conse-
quences of such changes in miR-133a levels are unknown, but it
has been suggested that uncoupling protein (UCP)-2 is a miR-133a
target, and that high miR-133a levels result in a decrease in UCP-
2 [47]. UCP-2 is also expressed in islet cells and is activated by
reactive oxygen species (ROS), thereby decreasing mitochondrial
ROS production [48]. Assuming that miR-133a also targets UCP-
2 in islet cells, high glucose-induced increase in miR-133a may
result in lower UCP-2 activity and higher ROS production,
contributing to glucotoxicity. Further studies on the consequences
of miR-133a-mediated reduction on UCP-2 levels in human islet
cells are warranted.
MiR-124a is highly expressed and targets PTB in neuronal cells
[32]. In insulin producing cells miR-124a may directly target the
secretory vesicle protein Rab27A [49] and the transcription factor
FoxA2 [50], possibly leading to alterations in beta-cell differen-
tiation, glucose metabolism and insulin release. A high glucose
concentration upregulates mir-124a in a mouse beta-cell line [37].
In the present study, a high glucose concentration induced miR-
124a only in islet from some of the donors. Also the islet miR-133a
response to sodium palmitate was highly inconsistent from one
donor to another. The reason for this inter-donor variability is not
clear, but variability in cellular composition and metabolic or
functional status might have influence the response to high glucose
and sodium palmitate. Nevertheless, in previous studies over-
expression of miR-124a in insulin producing cells resulted in
perturbations in calcium levels and glucose-induced insulin release
[49,50], indicating a negative impact of an increased level of miR-
124a on islet cell function.
MicroRNA-146 levels increase in response to cytokines in
rodent beta-cells and human islets [33] and to sodium palmitate in
rodent beta-cells [49]. These effects of cytokines were confirmed
by our data, whereas the effects of sodium palmitate were at
variance with the present investigation. The reason for this
discrepancy is unclear, but it may be that human and rodent islet
cells react differently to sodium palmitate. Cytokine-induced miR-
146 induction mediates feed back inhibition of interleukin-1
receptor- and Toll-like receptor-induced signaling by promoting
down-regulation of IRAK and TRAF6 [33]. Cytokine-induced
up-regulation of miR-146 has been suggested to enhance beta-cell
destruction [33], but it is also possible, at least in theory, that miR-
146 induction and IRAK + TRAF6 down-regulation leads to
increased resistance to cytokines.
In the present investigation, human islets responded with a
markedly decreased miR-146 level in response to a high glucose
concentration. This finding could be of considerable importance to
our understanding of Type 2 diabetes. Hyperglycemia has been
suggested to mediate islet inflammation and beta-cell dysfunction
in Type 2 diabetes by increasing islet interleukin-1 production [2].
Our finding points to the novel possibility that high glucose
concentrations increase islet sensitivity to interleukin-1- and Toll-
like receptor activation by counteracting miR-146-induced down-
regulation of IRAK and TRAF6. Further studies in the field of
miRNA-mediated control of islet cytokine-signaling are needed to
clarify these questions.
In conclusion, we report for the first time the existence of a
miRNA-regulated mechanism in human islet cells that mediates
Table 2. Effects of miR-133a precursor and miR-133 inhibitor on human islet insulin biosynthesis.
5.6 mM Glucose
with miR control
20 mM Glucose
with miR control
5.6 mM Glucose
with miR-133a
precursor
20 mM Glucose
with miR-133a
precursor
5.6 mM Glucose
with miR-133a
inhibitor
20 mM Glucose
with miR-133a
inhibitor
Insulin Biosynthesis
(DPM/islet)
637665 410655* 463645 335635* 6756123 5046113
Total Protein
Biosynthesis (DPM/islet)
62836529 54966808 59706609 57316925 675461583 516761242
Human islets were transfected with miR-133a precursor or inhibitor for two days and then cultured for 24 hours at 5.6 or 20 mM glucose. Insulin and total protein
biosynthesis was quantified as given above using 10–20 islet equivalents per group. Results are means 6 SEM for 3–4 observations.
*denotes p,0.05 using Student’s t-test when comparing vs. control. The percentages insulin biosynthesis per total protein biosynthesis in these experiments are given
in Figure 5B.
doi:10.1371/journal.pone.0010843.t002
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impact of the high glucose-induced increase in miR-133a on
insulin biosynthesis rates was not dramatic, but this mechanism
may act in synergy with other high glucose-induced suppressive
mechanisms leading to beta-cell failure and aggravation of Type 2
diabetes. Finally it is possible that other miRNA-controlled
mechanisms participate in high glucose-induced beta-cell dysfunc-
tion. For example, miR-146-mediated control of cytokine-
receptor-signaling events may regulate beta-cell sensitivity to
inflammatory factors, and miR-133a targeting of UCP-2 may
control mitochondrial output of ROS.
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